EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

How to Safely Anticoagulate Patients With Renal Impairment

Nadir Aziz, Robyn Haysom, Jecko Thachil, Dawn Swan

British Journal of Hospital Medicine · 24.07.2026 · 87 (7)

DOI: 10.31083/bjhm49737 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift British Journal of Hospital Medicine, online erschienen am 24.07.2026. Verfasst von Nadir Aziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, University Hospitals Coventry and Warwickshire NHS Trust, CV2 2DX Coventry, UK. Hauptthemen laut MEDLINE: Anticoagulants, Venous Thromboembolism, Renal Insufficiency, Chronic. Die Arbeit nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic kidney disease (CKD), a highly prevalent condition worldwide, is associated with increased thrombotic and bleeding risks. Thrombotic risks include heightened cardiovascular risk and that of venous thromboembolism, driven by endothelial dysfunction, and inflammation. Conversely, platelet dysfunction and vascular abnormalities elevate the bleeding risk. This complex interplay of bleeding and thrombosis highlights the challenges faced in anticoagulant prescribing in CKD. Although warfarin and low-molecular-weight heparin are currently recommended in the guidelines, direct oral anticoagulants (DOACs) may offer a favourable profile in mild-to-moderate CKD based on the decreased incidence of thrombotic events and lower bleeding risk reported in studies. There remains a paucity of studies on DOAC use in severe CKD and end-stage renal disease (ESRD). In this article we discuss different options of anticoagulant use in the setting of CKD for venous thromboembolism (VTE) treatment and prophylaxis in atrial fibrillation (AF), highlighting the need for further clinical trials in this patient population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsVenous ThromboembolismRenal Insufficiency, ChronicHumansHemorrhageAtrial FibrillationWarfarinKidney Failure, ChronicHeparin, Low-Molecular-Weight

Stichwörter der Autor:innen

CKDESRDanti-Xaanticoagulationhaemorrhage

Substanzen

AnticoagulantsWarfarinHeparin, Low-Molecular-Weight

Autor:innen und Institutionen

  • Department of Gastroenterology, University Hospitals Coventry and Warwickshire NHS Trust, CV2 2DX Coventry, UK.
  • School of Medical Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, M13 9PL Manchester, UK.
  • Department of Geriatric Medicine, University Hospitals of North Midlands NHS Trust, ST4 6QG Stoke-on-Trent, UK.
  • Department of Haematology, Manchester Royal Infirmary, M13 9WL Manchester, UK.
  • Faculty of Biology, Medicine and Health, The University of Manchester, M13 9PL Manchester, UK.
  • Department of Haematology, Austin Health, Melbourne, VIC 3084, Australia.

Zitieren

APA

Aziz, N., Haysom, R., Thachil, J., & Swan, D. (2026). How to Safely Anticoagulate Patients With Renal Impairment. British Journal of Hospital Medicine, 87(7). https://doi.org/10.31083/bjhm49737

Vancouver

Aziz N, Haysom R, Thachil J, Swan D. How to Safely Anticoagulate Patients With Renal Impairment. British Journal of Hospital Medicine. 2026;87(7). doi:10.31083/bjhm49737

BibTeX
@article{Aziz2026,
  author = {Aziz, Nadir and Haysom, Robyn and Thachil, Jecko and Swan, Dawn},
  title = {How to Safely Anticoagulate Patients With Renal Impairment},
  journal = {British Journal of Hospital Medicine},
  year = {2026},
  volume = {87},
  number = {7},
  doi = {10.31083/bjhm49737}
}
Kostenlos starten →